# RNA Therapeutics * **Definition:** Therapeutics based on RNA molecules designed to treat various diseases, including cancer and autoimmune disorders, often involving innovative delivery methods such as lipid nanoparticles. * **Taxonomy:** Healthcare Topics / RNA Therapeutics ## News * Selected news on the topic of **RNA Therapeutics**, for healthcare technology leaders * 1.4K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/29/2025 | [**Saudi Arabia RNA Therapeutics Market Research 2025 - Yahoo Finance**](https://finance.yahoo.com/news/saudi-arabia-rna-therapeutics-market-142600845.html) | [[Yahoo Finance]] | | 5/7/2025 | [**A Compelling AI Use Case for Health Insurers**](https://www.healthitanswers.net/a-compelling-ai-use-case-for-health-insurers/) | [[Health IT Answers]] | | 5/6/2025 | [**Vertical interconnected Clouds: The Right Prescription for Smarter, AI-Driven Healthcare?**](https://hitconsultant.net/2025/05/06/vertical-interconnected-clouds-the-right-prescription-for-smarter-ai-driven-healthcare/) | [[HIT Consultant]] | | 4/13/2025 | [**Newcastle biotech pioneer Nanovery seals £1.1m funding boost**](https://uk.news.yahoo.com/newcastle-biotech-pioneer-nanovery-seals-125458729.html) | [[Yahoo News UK]] | | 4/2/2025 | [**Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?**](https://finance.yahoo.com/news/argenx-se-argx-most-profitable-134751572.html) | [[Yahoo Finance]] | | 4/2/2025 | [**Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?**](https://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-most-134818781.html) | [[Yahoo Finance]] | | 4/2/2025 | [**Is United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now?**](https://finance.yahoo.com/news/united-therapeutics-corporation-uthr-most-134701676.html) | [[Yahoo Finance]] | | 4/2/2025 | [**Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?**](https://finance.yahoo.com/news/exelixis-inc-exel-most-profitable-134802137.html) | [[Yahoo Finance]] | | 4/2/2025 | [**Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?**](https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-most-134646594.html) | [[Yahoo Finance]] | | 4/2/2025 | [**Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now?**](https://finance.yahoo.com/news/royalty-pharma-plc-rprx-most-134738804.html) | [[Yahoo Finance]] | | 3/25/2025 | [**Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as Company Continues Evolution as an RNA Therapeutics CRDMO**](https://finance.yahoo.com/news/nutcracker-therapeutics-ceo-dr-igor-120000993.html) | [[Yahoo Finance]] | | 3/17/2025 | [**RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032 ...**](https://finance.yahoo.com/news/rna-therapeutics-market-expected-generate-140000877.html) | [[Yahoo Finance]] | | 3/13/2025 | [**NTx Establishes Scientific Advisory Board with Distinguished Leaders in Oncology**](https://finance.yahoo.com/news/ntx-establishes-scientific-advisory-board-130000339.html) | [[Yahoo Finance]] | | 2/6/2025 | [**Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity**](https://finance.yahoo.com/news/wave-life-sciences-announces-initiation-133000748.html) | [[Yahoo Finance]] | | 1/14/2025 | [**Healthcare Trends Shaping 2025 And Insights For Industry Leaders - Forbes**](https://www.forbes.com/councils/forbesbusinesscouncil/2025/01/14/healthcare-trends-shaping-2025-and-insights-for-industry-leaders/) | [[Forbes]] | | 1/14/2025 | [**Simnova and Orna Expand Strategic Partnership to Include BCMA-Targeted RNA Therapeutics**](https://finance.yahoo.com/news/simnova-orna-expand-strategic-partnership-120000931.html) | [[Yahoo Finance]] | | 1/1/2025 | [**Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?**](https://finance.yahoo.com/news/why-avidity-biosciences-inc-rna-181231072.html) | [[Yahoo Finance]] | | 12/12/2024 | [**NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors**](http://www.businesswire.com/news/home/20241212964506/en/NextRNA-Therapeutics-Appoints-Seasoned-Industry-Leader-Charles-Kunsch-Ph.D.-to-Board-of-Directors/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 10/8/2024 | [**CVS to lay off 632 at Rhode Island headquarters**](https://www.beckershospitalreview.com/pharmacy/cvs-to-lay-off-632-at-rhode-island-headquarters.html) | [[Beckers Hospital Review]] | | 9/9/2024 | [**RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI**](https://finance.yahoo.com/news/rna-therapeutics-market-size-expected-151000007.html) | [[Yahoo Finance]] | | 9/3/2024 | [**RNA Therapeutics Core launches at Mass General Brigham to boost circular RNA research**](https://www.news-medical.net/news/20240903/RNA-Therapeutics-Core-launches-at-Mass-General-Brigham-to-boost-circular-RNA-research.aspx) | [[News Medical Net]] | | 9/2/2024 | [**Where Tech Meets Bio (Substack Newsletter) on LinkedIn: Brief highlights from past week**](https://www.linkedin.com/posts/where-tech-meets-bio_brief-highlights-from-past-week-the-biopharma-activity-7236342749661147136-OazW) | [[Linkedin]] | | 7/30/2024 | [**Orna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, Ph.D., to Scientific Advisory Board**](https://www.prnewswire.com/news-releases/orna-therapeutics-appoints-nobel-laureate-carolyn-bertozzi-phd-to-scientific-advisory-board-302208897.html) | [[PR Newswire]] | | 7/14/2024 | [**RNA Therapeutics Market Size 2024 High-growth Segments and their Share Forecast till 2028**](https://www.whatech.com/og/markets-research/medical/855919-rna-therapeutics-market-size-2024-high-growth-segments-and-their-share-forecast-till-2028) | whatech.com | | 2/13/2024 | [**Revolutionizing Healthcare: The Integral Role Of AI And IoT In Shaping Modern Medicine**](https://www.forbes.com/councils/forbesbusinessdevelopmentcouncil/2024/02/14/revolutionizing-healthcare-the-integral-role-of-ai-and-iot-in-shaping-modern-medicine/) | [[Forbes]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **NextRNA Therapeutics**: A biotechnology company focused on developing small molecule therapeutics targeting long non-coding RNAs (lncRNAs) for oncology applications. - **City Therapeutics**: A biotech startup developing RNA interference (RNAi)-based medicines, led by industry veterans, aiming to enhance therapeutic potential of RNAi. - **Tiba Biotech LLC**: A preclinical biopharmaceutical company developing innovative RNA therapeutics against influenza. - **Myeloid Therapeutics**: A clinical-stage company focused on engineering RNA technology for cancer treatment. - **Orna Therapeutics**: Develops synthetic circular RNA therapeutics, aiming to revolutionize CAR therapies. - **Alnylam Pharmaceuticals**: A leader in RNA interference (RNAi) therapeutics, focusing on genetic diseases. - **Ractigen Therapeutics**: A company developing siRNA therapies for ALS, targeting the FUS gene. - **City Therapeutics, Inc.**: A company advancing RNA interference (RNAi)-based medicine, co-founded by John Maraganore, Ph.D., aiming to enhance therapeutic applications across various diseases. - **Sirnaomics Ltd.**: A biopharmaceutical company specializing in RNAi therapeutics, focused on developing innovative drugs for unmet medical needs. - **TransCode Therapeutics**: Develops RNA therapeutics targeting metastatic tumors using a proprietary delivery platform. - **Nutcracker Therapeutics**: Specializes in RNA precision manufacturing and aims to develop personalized RNA therapies. - **RiboX Therapeutics**: A company developing circular RNA therapeutics, currently in clinical trials for treating xerostomia in head and neck cancer patients. - **HAYA Therapeutics**: Focused on RNA-guided precision medicines, developing programmable therapeutics targeting long non-coding RNAs. - **Inverna Therapeutics**: A Danish biotech company focused on RNA therapeutics, particularly for severe genetic diseases like Huntington's disease, utilizing innovative RNA splicing modulation techniques. - **Sirnaomics**: Develops RNAi therapeutics and has partnerships to advance aesthetic medicine applications. - **Arcturus Therapeutics**: Focuses on messenger RNA medicines and has developed self-amplifying mRNA vaccines. ### Partnerships and Collaborations - **Hoth Therapeutics**: Collaborating with scientists and clinicians to develop impactful RNA therapies and improve patient quality of life. - **Bayer and NextRNA Therapeutics**: A collaboration worth over $547 million to develop small molecule drugs targeting lncRNAs in oncology, including two first-in-class programs. - **EnPlusOne and various RNA therapeutics companies**: Aiming to expand partnerships for enzymatic RNA synthesis. - **Nature's Toolbox (NTx)**: Established a Scientific Advisory Board to enhance RNA and protein manufacturing platforms. - **Tevard Biosciences and Vertex Pharmaceuticals**: A partnership aimed at developing tRNA-based therapies for genetic diseases. - **Ring Therapeutics**: Announced strategic partnerships with A*STAR and the Singapore Eye Research Institute to enhance gene therapy development. - **EnPlusOne Biosciences**: Actively partnering within the RNA therapeutic landscape to address manufacturing challenges and enhance RNA delivery. - **Sirnaomics and Gore Range Capital**: Establishment of Sagesse Bio, focusing on RNAi therapeutic products in aesthetic medicine. - **Aurora Biosynthetics and New South Wales Government**: Public-private partnership to enhance RNA manufacturing capabilities in the Asia-Pacific region. - **Orna Therapeutics and Shanghai Simnova Biotech**: Expanded collaboration to develop RNA-based therapeutics targeting B-cell maturation antigen (BCMA) for treating multiple myeloma, with Simnova focusing on Greater China. - **Orna Therapeutics and Dr. Carolyn Bertozzi**: Appointment of a Nobel Laureate to enhance circular RNA expression technologies. - **Triastek and BioNTech**: Collaboration to develop RNA therapeutics for oral delivery using 3D printing technology. - **Sheba Medical Center and Mana.bio**: Joint research to enhance AI-driven RNA delivery for cancer and autoimmune therapies. - **Nanjing Triastek and BioNTech**: Collaboration to develop oral RNA therapeutics using 3D printing technology. - **Primrose Bio and ExploRNA Therapeutics**: Partnering to develop and market products aimed at advancing mRNA therapies and vaccines. - **Arcturus Therapeutics and CSL Seqirus**: Collaboration for innovative mRNA vaccines. - **Tiba Biotech and BARDA**: Partnership to develop innovative therapeutics against influenza. - **Avestagenome Project and Tata Institute for Genetics and Society**: Partnering to advance research on rare genetic disorders, including exploring mRNA therapeutics. - **Sionna Therapeutics**: Aiming to partner for developing innovative cystic fibrosis medicines. ### Innovations, Trends, and Initiatives - **RNA Therapeutics Market Growth**: The global market for Antisense & RNAi Therapeutics is projected to grow significantly, driven by advancements in drug delivery technologies and increasing demand due to chronic diseases. - **RNA Therapeutics Core**: Launched by Mass General Brigham to advance RNA technologies for clinical applications. - **RNA Interference (RNAi) Advances**: City Therapeutics' engineering of siRNAs to enhance therapeutic potential in RNAi-based medicines. - **RNAi Therapeutics Development**: City Therapeutics aims to advance RNAi-based medicine through next-generation engineering of small interfering RNAs (siRNAs). - **RNA Interference Technologies**: Innovations in molecular biology and drug delivery systems are enhancing the effectiveness of RNAi therapeutics. - **Synthetic circular RNA therapeutics**: Orna Therapeutics is advancing a new class of RNA therapeutics that promise simplified production and superior protein expression. - **mRNA Vaccines**: The success of mRNA vaccines has spurred interest in RNA therapeutics for infectious diseases and oncology. - **Self-Replicating RNA Technology**: Replicate Bioscience's focus on enhancing RNA therapeutics through self-replicating RNA technology, showing promise in clinical trials. - **RNA Manufacturing Solutions**: Aurora's comprehensive GMP production capabilities to meet the growing demand for RNA-based therapies. - **AI in RNA Delivery**: Emerging trend of using AI to optimize RNA delivery systems for enhanced therapeutic efficacy. - **Regulatory Approvals**: RiboX Therapeutics' RXRG001 is the first circular RNA therapy to receive FDA IND clearance. - **Circular RNA Therapeutics**: Orna Therapeutics is developing circular RNA therapeutics, showcasing significant CRISPR editing rates. - **Delivery Systems**: Innovations in RNA delivery systems, such as lipid nanoparticles, are improving the bioavailability and effectiveness of RNA therapies. - **Market Growth**: The RNA therapeutics market is projected to grow at a CAGR of 9.4%, reaching USD 22.37 billion by 2032, driven by advancements in RNA-based drug development. - **RNA-based Vaccines**: Increased interest following the success of COVID-19 vaccines, leading to exploration in various diseases. - **Growth of RNA Therapeutics Market**: Projected to grow from USD 13.7 billion in 2023 to USD 18.0 billion by 2028, driven by technological advancements. - **Cationic polymers for RNA delivery**: Research at LMU is enhancing the effectiveness of RNA therapeutics through improved delivery mechanisms. - **3D Printing for RNA Delivery**: Triastek's innovative approach to optimize oral delivery of RNA therapeutics through unique tablet structures. - **Antibody Oligonucleotide Conjugates (AOCs)**: Avidity's development of AOCs to improve RNA therapy delivery to muscle tissues. ### Challenges and Concerns - **Regulatory Hurdles**: Emerging RNA-based therapies face significant regulatory challenges that could hinder their development and market entry. - **Market Competition**: The RNA therapeutics field is rapidly evolving, with numerous players vying for market share, necessitating continuous innovation. - **High costs of RNA therapeutics**: Despite advancements, the high costs of RNA-based treatments limit accessibility for many patients. - **Funding and Resource Allocation**: Concerns regarding constrained funding and the necessity for risk minimization in the rapidly evolving landscape of RNA therapeutics. - **High Costs**: The complexity and expense associated with RNA-based therapeutics may hinder broader adoption. - **Stability and Delivery**: Challenges in the stability and delivery of RNA therapies may hinder the development and commercialization of new treatments. - **Regulatory Uncertainties**: Ongoing regulatory uncertainties could impact the speed of bringing RNA therapeutics to market. - **High Development Costs**: The RNA therapeutics market faces challenges such as high production costs and complex regulatory frameworks. - **Delivery Efficiency**: Need for innovative engineering techniques to improve cellular uptake efficiency and reduce off-target effects in RNA therapeutics. - **Efficacy and Safety**: The need for improved protein expression and delivery efficiency in mRNA therapeutics while balancing efficacy and safety. - **Production Complexity**: Traditional RNA production methods are often costly and complex, which NTxscribe® aims to address by providing a more streamlined solution. - **Competition in the field**: Companies like Sarepta face competition from CRISPR/Cas9-based therapies and other gene therapy candidates. - **Manufacturing Scalability**: Ensuring scalable and sustainable manufacturing processes for RNA therapeutics remains a critical challenge. - **Stability and Efficacy**: Challenges in the stability of oligonucleotides and their susceptibility to degradation by nucleases, impacting therapeutic effectiveness. - **Concerns in Gene Therapy Development**: Setbacks in gene therapy trials, such as those by Pfizer and Sarepta, raise concerns about the viability of these treatments. - **Regulatory Changes in Europe**: Upcoming regulatory changes regarding health technology assessments may undervalue gene therapies and limit patient access. - **Funding Cuts**: NIH funding cuts may impact clinical research and the enforcement of diversity initiatives in the industry.